Comparative Pharmacology
Head-to-head clinical analysis: EXSERVAN versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXSERVAN versus KENALOG IN ORABASE.
EXSERVAN vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exservan (riluzole) is a benzothiazole derivative that modulates glutamatergic neurotransmission. Its mechanism of action involves inhibition of glutamate release, inactivation of voltage-dependent sodium channels, and interference with neurotransmitter binding to excitatory amino acid receptors.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Adults: 15 mg orally once daily in the morning; increase to 30 mg after 2 weeks if needed. Maximum 30 mg/day.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Terminal elimination half-life is approximately 3–4 hours in patients with normal renal function; prolonged in renal impairment (up to 8–10 hours in ESRD).
Terminal half-life approximately 2-5 hours following mucosal application.
Primarily renal excretion as unchanged drug: 80% excreted unchanged in urine; approximately 20% as metabolites; biliary/fecal <5%.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid